Article
Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study.
BMC cancer - 28 Oct 2022
Zhang Wen, Han Xiaohong, Yang Lin, Song Yuanyuan, Xie Liangzhi, Gai Wenlin, Wang Yan, Shi Yuankai
Abstract excerpt
BACKGROUND: An over-expression of the epidermal growth factor receptor (EGFR) has been observed in colorectal cancer and is associated with aggressive disease and poor prognosis. SCT200 is a newly developed recombinant, fully humanized, anti-EGFR monoclonal antibody. This study aimed to evaluate its safety, tolerability, pharmacokinetics (PK), and efficacy in patients with wild-type KRAS/NRAS/BRAF metastatic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.